In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From VBI Vaccines

Big Pharma Pacts Benefit From Reduced HBV Biologics Competition

Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.

Infectious Diseases Companies

EMA Thumbs Up For Idorsia’s Insomnia Drug And Immunocore’s Uveal Melanoma Treatment

An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.

Europe Approvals

Idorsia’s Insomnia Drug Daridorexant Among 14 Hopefuls For EU Verdict

The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.

Europe Approvals

CDC Panel Stops Shy Of Universal Adult Hepatitis B Vaccine Recommendation

ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.

Advisory Committees Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Variation Biotechnologies
UsernamePublicRestriction

Register